Literature DB >> 12701829

What is the 'right' dose of rifampin?

Charles Peloquin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12701829

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


× No keyword cloud information.
  31 in total

1.  Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Authors:  Ian M Rosenthal; Rokeya Tasneen; Charles A Peloquin; Ming Zhang; Deepak Almeida; Khisimuzi E Mdluli; Petros C Karakousis; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

Review 2.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

Review 3.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

4.  Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

Authors:  Ian M Rosenthal; Kathy Williams; Sandeep Tyagi; Charles A Peloquin; Andrew A Vernon; William R Bishai; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2006-03-30       Impact factor: 21.405

5.  Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis.

Authors:  Rovina Ruslami; Hanneke Nijland; Rob Aarnoutse; Bachti Alisjahbana; Arto Yuwono Soeroto; Suzanne Ewalds; Reinout van Crevel
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

6.  Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.

Authors:  A H Diacon; R F Patientia; A Venter; P D van Helden; P J Smith; H McIlleron; J S Maritz; P R Donald
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

Review 7.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

8.  Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Authors:  Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

Review 9.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

10.  A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.

Authors:  Elsje Pienaar; Nicholas A Cilfone; Philana Ling Lin; Véronique Dartois; Joshua T Mattila; J Russell Butler; JoAnne L Flynn; Denise E Kirschner; Jennifer J Linderman
Journal:  J Theor Biol       Date:  2014-12-09       Impact factor: 2.691
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.